|Articles|April 16, 2020
CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data
Author(s)OncLive Staff
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 19, 2020 at 8 PM EST.
Advertisement
Date/Time: Tuesday, May 19, 2020 at 8 PM EST
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells.
The following objectives will be reviewed:
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells.
The following objectives will be reviewed:
- Review of available therapies, indications, and eligible patient populations
- Examine real-world data associated with available CAR T-cell therapies
- Improving access and overcoming barriers to CAR T-cell therapy
We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.
Faculty:
Loretta J. Nastoupil, MD, Associate Professor; Section Chief, Indolent Lymphoma; Section Chef, New Drug Development, Department Lymphoma/Myeloma, UT MD Anderson Cancer Center
Ahmed Galal, MD, FRACP, MSc, Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Duke School of Medicine
Matthew Lunning, DO, Associate Professor, Internal Medicine; Medical Director, Lymphoma Research, Division of Oncology & Hematology, University of Nebraska Medical Center
Sponsored By:
Faculty:
Loretta J. Nastoupil, MD, Associate Professor; Section Chief, Indolent Lymphoma; Section Chef, New Drug Development, Department Lymphoma/Myeloma, UT MD Anderson Cancer Center
Ahmed Galal, MD, FRACP, MSc, Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Duke School of Medicine
Matthew Lunning, DO, Associate Professor, Internal Medicine; Medical Director, Lymphoma Research, Division of Oncology & Hematology, University of Nebraska Medical Center
Sponsored By:
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- CGTLive®’s Weekly Rewind – September 5, 2025
September 5th 2025
- CGTLive®’s Weekly Rewind – August 29, 2025
August 29th 2025
- Unmet Needs Following Early-Line CAR-T for R/R Multiple Myeloma
August 27th 2025
Advertisement
Advertisement